Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study

Kenji Tanabe,Shuichiro Kobayashi, Yuya Maezawa, Kensaku Ishihara, Naoki Inoue,Keita Izumi,Motohiro Fujiwara,Masahiro Toide, Takanobu Yamamoto,Sho Uehara,Saori Araki,Masaharu Inoue,Ryoji Takazawa,Noboru Numao, Yukihiro Ohtsuka,Hajime Tanaka,Soichiro Yoshida,Yasuhisa Fujii

International Journal of Clinical Oncology（2024）

Cited 0|Views7

No score

Abstract

This study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab. This multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic UC treated with pembrolizumab after platinum-based chemotherapy between January 2018 and June 2023 at 13 institutions. We collected pretreatment variables, including the GRIm-score based on serum albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio. The patients were divided into low and high GRIm-score groups. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were determined using the multivariate Cox proportional hazard model. During the median follow-up period of 7.3 months, 278 (84

Translated text

Key words

Immune checkpoint inhibitors,Metastasis,Prognosis,Transitional cell carcinoma

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined